Abstract
Purpose of review: Welsh immunodeficient patients on immunoglobulin replacement therapy (IgRT) who were considered high risk for severe coronavirus disease 2019 (COVID-19) were directed to shield. Consequently, patients receiving hospital-based intravenous immunoglobulin (IVIg) quickly transitioned to home-based self-administered subcutaneous immunoglobulin (SCIg). This evaluation aimed to assess patients’ perceptions and experiences and laboratory outcomes of emergency IgRT transition during COVID-19.
Recent findings: A quick transition from in-hospital IVIg to home-based rapid push SCIg is achievable, however, patient IgRT administration preference remains key outside of emergency shielding measures.
Summary: Subjective self-reported experiences ( n = 23) and objective immunoglobulin G (IgG) concentration ( n = 28) assessments were prospectively collected from patients pre/post-IgRT switch. In total, 41/55 (75%) patients transitioned from IVIg to rapid push SCIg and all completed training to self-administer subcutaneously within 24 days. Twenty-two percent ( n = 5) of patients preferred SCIg and 35% ( n = 8) wanted to return to hospital-based IVIg at 6 weeks post-transition. Mean IgG levels were similar pre vs. post-SCIg switch (10.3 g/l vs. 10.6 g/l, respectively). Patients reported greater infection anxiety during COVID-19 and adapted behaviours to mitigate risk. Although a third of patients wished to return to IVIg following cessation of shielding, over time the percentage electing to remain on SCIg rose from 22% to 59%.
【초록키워드】 COVID-19, IgG, Intravenous immunoglobulin, Anxiety, Infection, risk, outcome, IVIG, Laboratory, Measures, Immunoglobulin, Patient, assessment, administration, Concentration, high risk, In-hospital, shielding, severe coronavirus disease, mitigate, recent, immunoglobulin replacement therapy, greater, collected, reported, receiving, IgG level, immunodeficient patient, subcutaneously, Subjective, transitioned, 【제목키워드】 coronavirus disease, Patient, intravenous, shielding, immunoglobulin replacement therapy,